anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Calcium pyrophosphate deposition (CPPD) disease was associated with osteopenia in two cross-sectional studies. We compared fracture risks in patients with acute calcium pyrophosphate (CPP) crystal arthritis versus matched comparators.
METHODS: We performed a longitudinal cohort study using electronic health record data from a single large academic health system, with data from 1991 to 2023. Patients with one or more episodes of acute CPP crystal arthritis were matched to comparators on the index date (first documentation of "pseudogout" or synovial fluid CPP crystals or matched encounter) and first encounter in the health system. The primary outcome was first fracture at the humerus, wrist, hip, or pelvis. We excluded patients with fracture before the index date. Covariates included demographics, body mass index, smoking, comorbidities, health care use, glucocorticoids, and osteoporosis treatments. We estimated incidence rates and adjusted hazard ratios for fracture. Sensitivity analyses excluded patients prescribed glucocorticoids, patients prescribed osteoporosis treatments, or patients with rheumatoid arthritis and additionally adjusted for chronic kidney disease.
RESULTS: We identified 1,148 patients with acute CPP crystal arthritis matched to 3,730 comparators, with a mean age of 73 years. Glucocorticoids and osteoporosis treatments were more frequent in the acute CPP crystal arthritis cohort. Fracture incidence rates were twice as high in the acute CPP crystal arthritis cohort (11.7 per 1,000 person-years) versus comparators (5.5 per 1,000 person-years). After multivariable adjustment, fracture relative risk was twice as high in the acute CPP crystal arthritis cohort (hazard ratio 1.8 [95% confidence interval 1.3-2.3]); results were similar in sensitivity analyses.
CONCLUSION: In this first published study of fractures and CPPD, fracture risk was nearly doubled in patients with acute CPP crystal arthritis.
Ubiquitin C-terminal hydrolase L1 (UCHL1) is a deubiquitinating enzyme originally found in the brain. Our previous work revealed that UCHL1 was also expressed in skeletal muscle and affected myoblast differentiation and metabolism. In this study, we further tested the role of UCHL1 in myogenesis and muscle regeneration following muscle ischemia-reperfusion (IR) injury. In the C2C12 myoblast, UCHL1 knockdown upregulated MyoD and myogenin and promoted myotube formation. The skeletal muscle-specific knockout (smKO) of UCHL1 increased muscle fiber sizes in young mice (1 to 2 months old) but not in adult mice (3 months old). In IR-injured hindlimb muscle, UCHL1 was upregulated. UCHL1 smKO ameliorated tissue damage and injury-induced inflammation. UCHL1 smKO also upregulated myogenic factors and promoted functional recovery in IR injury muscle. Moreover, UCHL1 smKO increased Akt and Pink1/Parkin activities. The overall results suggest that skeletal muscle UCHL1 is a negative factor in skeletal muscle development and recovery following IR injury and therefore is a potential therapeutic target to improve muscle regeneration and functional recovery following injuries.
<P>PROBLEM TO BE SOLVED: To provide an excellent oral composition and food for the prevention or treatment of spots or freckles.  <P>SOLUTION: The invention provides an oral composition containing biotins, ascorbic acids and vitamin Es as active components and effective for the prevention or treatment of spots or freckles, and a food containing biotins, ascorbic acids and vitamin Es as active components. The administration doses of biotins and ascorbic acids are preferably 0.0005-5 mg and 10-3,000 mg per day, respectively. The composition, etc., preferably contains 40-300,000 pts.wt. of ascorbic acids and 2-30,000 pts.wt. of vitamin Es based on 1 pt.wt. of biotins. The combined use of biotins, ascorbic acids and vitamin Es effectively suppresses spots and freckles.  <P>COPYRIGHT: (C)2007,JPO&INPIT
A new family of compounds, method of obtaining them and their uses in the treatment and/or prophylaxis of diseases. The present invention describes compounds of formula (I) and pharmaceutical compositions containing it. It also describes a process for obtaining said compounds of formula (I). Finally, the present invention deals with the use of said compounds and of the pharmaceutical compositions containing them, for preparing a medicament. Especially drugs intended for the treatment and/or prophylaxis of diseases derived from the anomalous transport of anions at cellular level, and more specifically to those intended for the treatment and/or prophylaxis of cystic fibrosis. (Machine-translation by Google Translate, not legally binding)
BACKGROUND: Robotic pancreatoduodenectomy is an increasingly accepted alternative for the treatment of pancreatic ductal adenocarcinoma (PDAC).1 However, the ability to perform a meticulous robotic-assisted superior mesenteric artery (SMA) dissection to obtain a margin-negative resection remains unknown.2 PDAC within the head of the pancreas (HOP) that involves the superior mesenteric vein (SMV) and portal vein (PV) requires total venous control (TVC) and a 'vein-to-the-right' (or anterior artery-first) approach to SMA dissection to minimize venous congestion and operative blood loss.3-5 Here, we demonstrate a robotic pancreatoduodenectomy with TVC and a 'vein-to-the-right' approach.
METHODS: A 70-year-old woman with cT2N0M0 HOP PDAC with lateral SMV involvement and right gastroepiploic vein occlusion underwent robotic pancreatoduodenectomy after neoadjuvant chemotherapy. After transecting the pancreas, we achieved TVC by dividing the small venous tributaries and encircling the SMV, splenic vein, and PV. We then proceeded with a 'vein-to-the-right' approach. The inferior pancreatoduodenal arteries were divided to minimize HOP inflow and decrease specimen bleeding. Once the specimen was dissected off the periadventitial plane of the distal SMA, the SMV dissection was carefully performed using a partial side-wall vein resection using a vascular stapler.
RESULTS: Total operative time was 7.5 h and estimated blood loss was 25 mL. The patient recovered well postoperatively and was discharged on postoperative day 3. Final pathology exhibited a 2.4 cm, moderately to poorly differentiated adenocarcinoma with negative margins (ypT2N1, 2/38 lymph nodes positive).
CONCLUSION: For tumors with lateral vein involvement, robotic pancreatoduodenectomy can be safely performed via TVC and a 'vein-to-the-right' approach.
PURPOSE:An embrocation, obtained by mixing specific vegetable oil with a hair, e.g. washed and sterilized animal hair, boiling the resultant mixture oil under agitation and heating, dissolving the hair, e.g. animal hair, in the oil, cooling the above-mentioned oil, and having drug effect, e.g. rapid curing action without side effects. CONSTITUTION:A medicinal embrocation obtained by mixing a vegetable oil, e.g. drying oil such as linseed oil, perilla oil or tung oil, or non-drying oil such as olive oil, camellia oil or peanut oil, with washed and sterilized animal hair, preferably hair of a female 13-22 years old, containing much sulfur, and formed of keratin which is a very stable hard protein, agitating the resultant mixture, heating slowly the mixture oil, dissolving the hair, e.g. animal hair, in the oil without leaving the shape under occasional agitation, cooling the resultant solution to ordinary temperature by natural heat radiation after the complete dissolution, and useful for cuts or dermatopathy, etc.
BACKGROUND: The TRPV1 receptor is a key molecule in pain generation. Previous development of oral TRPV1-antagonists was halted due to systemic heat insensitivity and body temperature alterations. The present Phase 1b study investigated the efficacy, safety and plasma exposure of a topically administered TRPV1-antagonist (ACD440 Gel) in healthy subjects.
METHODS: The study comprised two parts. In part 1, 24 healthy subjects were included in this randomized double-blind, placebo-controlled, crossover trial. ACD440 Gel or Placebo was applied once daily and wiped off after 1 h, for 5 consecutive days. Assessments were done in normal skin, skin optimized for penetration (by stripping and occlusive gel application) and UVB-irradiated skin. Pain induced by thermo-nociceptive CO2 laser impulses generated laser-evoked potentials (LEPs), with readouts of peak-to-peak (PtP) amplitude in vertex-EEG and pain assessments by VAS (0-100). Endpoints include effects at 1 hour post-dose, AUC(Days 1-5) and AUC(0-24, Day 4). In UVB-irradiated skin, also pain on pinprick and skin redness were assessed. Part 2 explored the plasma pharmacokinetics of ACD440.
RESULTS: ACD440 Gel reduced LEP PtP amplitude and VAS pain, p < 0.001, in all skin conditions, versus placebo. In UVB-irradiated skin, pinprick pain was also reduced, p = 0.047. Effects were significant after 1 h, maintaining for at least 9 h. There were no adverse events or drug-induced erythema. Plasma exposures of ACD440 were too low to establish an elimination half-life of ACD400.
CONCLUSIONS: Topical ACD440 Gel demonstrated a significant analgesic effect on LEP, VAS score and pinprick pain, with low systemic exposures, supporting further clinical development.
SIGNIFICANCE: This study demonstrates that the topical administration of a TRPV1-antagonist, ACD440 Gel, has potential as a new treatment for painful conditions affecting the skin, such as chronic peripheral neuropathic pain, without any local or systemic side effects.
The dosage of TIROSINT-SOL for hypothyroidism or pituitary TSH suppression depends on a variety of factors including: the patient's age, body weight, cardiovascular status, concomitant medical conditions (including pregnancy), concomitant medications, co-administered food, and the specific nature of the condition being treated [see Dosage and Administration (2.3), Warnings and Precautions (5), and Drug Interactions (7)] . Dosing must be individualized to account for these factors and dosage adjustments made based on periodic assessment of the patient's clinical response and laboratory parameters [see Dosage and Administration (2.4)] .

For adult patients with primary hypothyroidism, titrate until the patient is clinically euthyroid and the serum TSH returns to normal [see Dosage and Administration (2.3)].

For secondary or tertiary hypothyroidism, serum TSH is not a reliable measure of TIROSINT-SOL dosage adequacy and should not be used to monitor therapy. Use the serum free-T4 level to titrate TIROSINT-SOL dosing until the patient is clinically euthyroid and the serum free-T4 level is restored to the upper half of the normal range [see Dosage and Administration (2.3)].

The peak therapeutic effect of a given dose of TIROSINT-SOL may not be attained for 4 to 6 weeks.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely gynaecology, and may be used for treating the patients with chronic non-specific endometritis. The method is implemented as follows: a therapeutic agent that is polyvalent complex pyobacteriophage in a dose of 4-7 ml is introduced in a female patient with a completely empty bladder on the 5-7postmenstrual day. There are 5 procedures of administering pyobacteriophage required. That is followed by the exposure to low-intensity infrared pulse laser at wave length 0.89 mcm, frequency 80 Hz, pulse power 5 Wt; the cutaneous daily 10-minute exposure covers the underbelly. For the 5 of 10 minutes, the exposure covers a projection of the uterus, while for the rest 5 minutes, a projection of the annexes are exposed. The therapeutic course is 10 procedures. Besides, the underbelly exposure is combined with the daily exposure covering a projection of the cubital vessels and the suprasternal notch for 2-3 minutes with the therapeutic course making 10 procedures. The exposure on a projection of the cubital vessels and the suprasternal notch may be both combined with the underbelly exposure, and follow the same.EFFECT: method provides the clinical effectiveness and provides ensures reducing the clinical manifestations of the disease, improving the ultrasound, doppler and laboratory parameters, normalising the genital micro-biocoenosis, optimising the female reproductive functions in a combination with a low rate of potential systemic side effects.3 cl, 3 ex
The invention relates to a preparation method of traditional Chinese medicine for treating spontaneous-perspiration-type colonitis, which belongs to the technical field of the traditional Chinese medicine preparation method. The existing method generally adopts ofloxacin to treat the spontaneous-perspiration-type colonitis, but gastrointestinal adverse reactions such as occasional headache, insomnia and change of liver function are always caused. The technical scheme adopted by the invention is that: radix pseudostellariae, black-bone chicken, wild cabbage, longan pulp, rhizoma atractylodis macrocephalae, white poeny, American ginseng, Chinese angelica, lotus seeds, codonopsis pilosula, sharpleaf galangal fruits, astragalus mongholicus, rhizoma polygonati, polished round-grained rice, dry gingers, fructus kochiae, oleander, persicaria perfoliata, junci medulla, Jiangxi desmodium, caulis aristolochiae manshuriensis, phaseolus calcaratus, longhairy antenoron herb, rhizoma alismatis, wartwort, poria cocos, pyrrosia lingua and liquorice are placed into water to be soaked and then to be decocted with slow fire, and the decocted liquid medicine is the traditional Chinese medicine for treating the spontaneous-perspiration-type colonitis. The preparation method has the advantages that the prepared traditional Chinese medicine has short course of treatment and high curative rate. Monarch, minister, assistant and guide in the traditional Chinese medicine are just perfect. By utilizing the traditional Chinese medicine, adverse reactions, anaphylactic reactions and toxic reactions caused by the Western medicine antibiotics can be avoided.
Although neurodevelopmental disorders are very prevalent (for example Autism affects 1 out of every 88 children and dyslexia affects up to 15% of the population), the etiology of such disorders is not known. The purpose of this investigation is to identify common etiologies of neurodevelopmental disorders (i.e., speech delay, global developmental delay, autism) and determine if it is possible to find early indicators of the diagnosis and foster the potential for a better prognosis of these disorders. At this time the investigators examine patients with neurodevelopment disorders with various medical investigations, but the results of these investigations are not systematically evaluated. One of the goals of this research is to systematically examine this information in order to identify patterns of test abnormalities that have not been previously described. Another goal of this research is to identify the common etiologies typically identified by the medical evaluation, so we can further refine our approach. In addition, the investigators now have the ability to evaluate biological samples for biomarkers that have potential to be diagnostically useful.
Co-polymers are formed by the polymerization of approximately equimolar amounts of a half-ester of an a , b -unsaturated carboxylic acid and a water-insoluble monomeric vinyl compound in the presence of a small amount (0,1 to 0,3 mole per mole of half ester) of acrylic and/or methacrylic acid.  Polymerization may be carried out in a suitable solvent, e.g. esters, ketones, alcohols or low aliphatic hydrocarbon halides (or mixtures thereof) in the presence of a catalyst e.g. organic peroxides, hydroperoxides, azo compounds, inorganic "per" compounds such as hydrogen peroxide.  Specified half-esters are those of maleic, fumaric and itaconic acids with C1-8 aliphatic alcohols. Specified vinyl compounds are styrene and its derivatives, vinyl esters, acrylic esters, methacrylic esters and vinyl chloride.  An example relates to the preparation of a preferred co-polymer using butyl maleate half-ester (9,000 gms.), styrene (6,920 gms.) and anhydrous methacrylic acid (1,000 gms.) in dioxan with benzoyl peroxide (51 gms.) as catalyst at 105 DEG C. for 15 hours. Plasticizers, e.g. fatty oils, fatty acids, polyhydric alcohols, solid hydrocarbons, dioctyl phthalate, sorbitan trioleate and glyceryl monostearate may be incorporated into the polymers.  The products find application as compositions with and as coatings on pharmaceutical agents.ALSO:Solid pharmaceutical preparations, e.g. tablets, pills, and granules, are granulated with or enterically coated by conventional methods, e.g. pan-coating, with a protective layer or layers of a copolymer formed by the polymerization of approximately equimolecular amounts of a half-ester of an a ,b -unsaturated dicarboxylic acid and a water-soluble monomeric vinyl compound in the presence of a small amount (0.1 to 0.3 mol. per mol. of half ester) of acrylic and/or methacrylic acid. Suitable hemi-esters are those of maleic, fumaric and itaconic acids with C1-8 aliphatic alcohols, suitable vinyl compounds are styrene and derivatives thereof, acrylic and methacrylic esters and vinyl chloride.  A preferred copolymer comprises 1.1 mols. styrene, 0.1 to 0.3 mol. methacrylic acid and 1 mol. of the butyl half-ester of maleic acid.  The coating material of the invention may also be dissolved in a solvent together with a solid hydrocarbon or with glyceryl monostearate or aliphatic acids of high molecular weight and the resulting solution used for coating.  Plasticizers may also be incorporated, examples of those given being fatty oils, fatty acids, polyhydric alcohols, solid hydrocarbons, dioctyl phthalate, sorbitan trioleate, glyceryl monostearate.  Specific medicaments mentioned are: para-aminosalicylic acid, phenyl-ethyl-barbituric acid and 7-chloro-4-(41-diethylamino-11 - methyl - butylamino) - quinoline diphosphate.
Infections and inflammatory reactions in the male genital tract are the leading causes of male infertility with a prevalence of 6%-10%, primarily affecting testicular and epididymal function and ultimately compromising sperm quality. However, most infertile patients with genital infection/inflammation are asymptomatic and easily overlooked. Traditional indicators, including white blood cells, elastase, and other components in semen, can reflect inflammation of the genital tract, but there is still a lack of a uniform standard method of detection. Therefore, it is necessary to explore reliable markers in semen that reflect the inflammatory status of the genital tract. Using the experimental autoimmune orchitis (EAO) model to simulate noninfectious chronic orchitis, we successfully collected ejaculated seminal fluid from EAO rats using optimized electrical stimulation devices. Proteomic analysis was performed using isobaric tags for relative and absolute quantification (iTRAQ). Compared to the control group, 55 upregulated and 105 downregulated proteins were identified in seminal plasma samples from the EAO group. In a preliminary screening, the inflammation-related protein S100A8/A9 was upregulated. We further verified that S100A8/A9 was increased in seminal plasma and highly expressed in testicular macrophages of the EAO model. In patients with oligoasthenospermia and genital tract infections, we also found that S100A8/A9 levels were remarkably increased in seminal plasma and testicular macrophages. S100A8/A9 in semen may be a potential biomarker for chronic genital inflammation. Our study provides a new potential biomarker for early diagnosis and further understanding of male infertility caused by genital inflammation.
Carbidopa and levodopa extended-release tablets are an extended-release combination of carbidopa and levodopa for the treatment of Parkinson’s disease and syndrome.

Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.24. It is designated chemically as (-)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxybenzene) propanoic acid monohydrate. Its empirical formula is C10H14N2O4•H2O and its structural formula is:

Tablet content is expressed in terms of anhydrous carbidopa, which has a molecular weight of 226.23.

Levodopa, an aromatic amino acid, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.2. It is designated chemically as (-)-L-α-amino-β-(3,4-dihydroxybenzene) propanoic acid. Its empirical formula is C9H11NO4 and its structural formula is:

Carbidopa and levodopa extended-release tablets are supplied as extended-release tablets containing 50 mg of carbidopa and 200 mg of levodopa. Inactive ingredients: colloidal silicon dioxide, D&C Yellow No. 10, FD&C Red No. 3, fumaric acid, hypromellose, and sodium stearyl fumarate.

The carbidopa and levodopa extended-release tablet is a polymeric-based drug delivery system that controls the release of carbidopa and levodopa as it slowly erodes. The 50 mg/200 mg half-tablet (bisect) will facilitate a 25 mg/100 mg tablet dose.
Intravitreal injections (IVI s) have gained increased popularity in the past decades and are used to treat a multitude of ailments. In 2010, the total number of IVI s surpassed the number of cataract surgeries performed, making it the most common procedure in ophthalmology. As the number of injections increases, so does the number of injected-related complications. While complications in the posterior segment, such as retinal detachment or endophthalmitis, are detrimental to visual function and have therefore been well documented, IVI s can also lead to complications in the anterior segment. These include hyphema, inflammation of the sterile anterior segment (incidence rate of 0.05 to 1.1% depending on the drug), implant migration with corneal decompensation (incidence rate of 0.43%), iatrogenic lens damage (incidence rate of 0.07%), accelerated cataract formation (up to 50% for steroids and 10.9% for anti-VEGF), and an increased complication rate during subsequent cataract surgery (up to 4% per IVI). Most of these complications occur immediately and have a good prognosis if treated correctly. However, the increased risk of complications during subsequent surgery demonstrates that IVI s can also have long-term complications, a topic that needs to be explored further in future research projects.
Disclosed are a system and a method that includes a robotic unit configured to deliver items (e.g., medicine, foodstuff, linens, equipment, etc.) to sites (e.g., rooms, offices, etc.) and/or individuals (e.g., patients, pharmacists, technician, etc.) throughout a facility (e.g., hospital, office building, mailroom, manufacturing facility, etc.). The robotic unit is a mobile unit that operates autonomously to follow predetermined or programmed routes throughout the facility to deliver the items. The system is configured to maintain a chain of custody for the items. In addition, the robotic unit is configured to only allow designated items to be delivered to designated sites and/or to authorized individuals. This can be achieved by the robotic unit having a plurality of containers that are locked within a storage space of the robotic unit, and are only accessible upon successful completion of an authorization process.
PURPOSE: A composition containing Alpiniae Semen organic solvent extract is provided to prevent and treat prostate cancer. CONSTITUTION: A composition for preventing and treating prostate cancer contains Alpiniae Semen organic solvent extract as an active ingredient. The organic solvent is 95% ethanol. The ethanol extract is prepared by isolating Alpiniae Semen at 50°C for 24 hours and drying the extract at 45°C. The composition contains pharmaceutically acceptable carrier or diluents. A functional food for preventing prostate cancer contains the extract and sitologically acceptable food additives as an active ingredient.